abcam

Product datasheet

Anti-p53 (phospho S37) antibody [EPR17353] ab182164

ועלשעבע RabMAb

★★★★ 1 Abreviews 画像数7

製品の概要

製品名 Anti-p53 (phospho S37) antibody [EPR17353]

製品の詳細 Rabbit monoclonal [EPR17353] to p53 (phospho S37)

由来種 Rabbit

アプリケーション 適用あり: Dot blot. WB

種交差性 交差種: Human

免疫原 Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

ポジティブ・コントロール p53 transfected HEK-293 whole cell lysate treated with UV (60 J/M2) for 2 hours; HEK-293 and

A431 whole cell lysates.

特記事項 This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility

- Improved sensitivity and specificity

- Long-term security of supply

- Animal-free production

For more information see here.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to **RabMAb**® **patents**.

製品の特性

製品の状態 Liquid

保存方法 Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long

term. Avoid freeze / thaw cycle.

バッファー pH: 7.2

Preservative: 0.01% Sodium azide

Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

精製度 Protein A purified

ポリモノ モノクローナル クローン名 EPR17353

アイソタイプ ΙgG

The Abpromise guarantee <u>Abpromise保証は、</u>次のテスト済みアプリケーションにおけるab182164の使用に適用されます アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。

アプリケーション	Abreviews	特記事項
Dot blot		1/1000.
WB		1/5000. Detects a band of approximately 53 kDa (predicted molecular weight: 43 kDa).

ターゲット情報

機能

Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a transactivator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Implicated in Notch signaling cross-over. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis.

組織特異性

Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.

関連疾患

Note=TP53 is found in increased amounts in a wide variety of transformed cells. TP53 is frequently mutated or inactivated in about 60% of cancers. TP53 defects are found in Barrett metaplasia a condition in which the normally stratified squamous epithelium of the lower esophagus is replaced by a metaplastic columnar epithelium. The condition develops as a complication in approximately 10% of patients with chronic gastroesophageal reflux disease and predisposes to the development of esophageal adenocarcinoma.

Defects in TP53 are a cause of esophageal cancer (ESCR) [MIM:133239].

Defects in TP53 are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is an autosomal dominant familial cancer syndrome that in its classic form is defined by the existence of a proband affected by a sarcoma before 45 years with a first degree relative affected by any tumor before 45 years and another first degree relative with any tumor before 45 years or a sarcoma at any age. Other clinical definitions for LFS have been proposed (PubMed:8118819 and PubMed:8718514) and called Li-Fraumeni like syndrome (LFL). In these families affected relatives develop a diverse set of malignancies at unusually early ages. Four types of cancers account for 80% of tumors occurring in TP53 germline mutation carriers: breast cancers, soft tissue and bone sarcomas, brain tumors (astrocytomas) and adrenocortical carcinomas. Less frequent tumors include choroid plexus carcinoma or papilloma before the age of 15, rhabdomyosarcoma before the age

of 5, leukemia, Wilms tumor, malignant phyllodes tumor, colorectal and gastric cancers. Defects in TP53 are involved in head and neck squamous cell carcinomas (HNSCC) [MIM:275355]; also known as squamous cell carcinoma of the head and neck. Defects in TP53 are a cause of lung cancer (LNCR) [MIM:211980].

Defects in TP53 are a cause of choroid plexus papilloma (CPLPA) [MIM:260500]. Choroid plexus papilloma is a slow-growing benign tumor of the choroid plexus that often invades the leptomeninges. In children it is usually in a lateral ventricle but in adults it is more often in the fourth ventricle. Hydrocephalus is common, either from obstruction or from tumor secretion of cerebrospinal fluid. If it undergoes malignant transformation it is called a choroid plexus carcinoma. Primary choroid plexus tumors are rare and usually occur in early childhood. Defects in TP53 are a cause of adrenocortical carcinoma (ADCC) [MIM:202300]. ADCC is a rare childhood tumor of the adrenal cortex. It occurs with increased frequency in patients with the Beckwith-Wiedemann syndrome and is a component tumor in Li-Fraumeni syndrome.

Belongs to the p53 family.

The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.

Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence.

Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP.

Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.

May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.

Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation. Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome. Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation. Deubiquitinated by USP10, leading to its stabilization. Ubiquitinated by TRIM24, which leads to proteasomal degradation. Ubiquitination by TOPORS induces degradation. Deubiquitination by USP7, leading to stabilization. Isoform 4 is monoubiquitinated in an MDM2-independent manner.

Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation. Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity. Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370. Dimethylated at Lys-373 by EHMT1 and EHMT2. Monomethylated at Lys-382 by SETD8, promoting interaction with L3MBTL1 and leading to repress transcriptional activity. Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation. Sumoylated by SUMO1.

Cytoplasm; Cytoplasm. Nucleus. Nucleus > PML body. Endoplasmic reticulum. Interaction with BANP promotes nuclear localization. Recruited into PML bodies together with CHEK2; Nucleus. Cytoplasm. Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the

配列類似性


ドメイン

翻訳後修飾

細胞内局在

nucleus that are different from nucleoli; Nucleus. Cytoplasm. Localized in the nucleus in most cells but found in the cytoplasm in some cells; Nucleus. Cytoplasm. Localized mainly in the nucleus with minor staining in the cytoplasm; Nucleus. Cytoplasm. Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4 and Nucleus. Cytoplasm. Predominantly nuclear but translocates to the cytoplasm following cell stress.

画像



Western blot - Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) **All lanes :** Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) at 1/1000 dilution

Lane 1: A431 whole cell lysate

Lane 2 : A431 treated with $1\mu g/ml$ doxorubicin for 24 hours whole cell lysate

Lane 3 : A431 treated with $1\mu g/ml$ doxorubicin for 24 hours whole cell lysate, the membrane was incubated with alkaline phosphatase.

Lysates/proteins at 10 µg per lane.


Secondary

All lanes : Goat Anti-Rabbit lgG H&L (HRP) (<u>ab97051</u>) at 1/20000 dilution

Predicted band size: 43 kDa **Observed band size:** 53 kDa

Exposure time: 15 seconds

Dilution and blocking buffer: 5% NFDM/TBST.



Western blot - Anti-p53 (phospho S37) antibody [EPR17353] (ab182164)

All lanes : Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) at 1/50000 dilution

Lane 1: p53 transfected HEK-293 whole cell lysate (Human epithelial cells from embryonic kidney)

Lane 2: p53 transfected HEK-293 whole cell lysate treated with UV (60 J/M2) for 2 hours

Lysates/proteins at 10 µg per lane.


Secondary

All lanes : Goat Anti-Rabbit lgG H&L (HRP) (<u>ab97051</u>) at 1/50000 dilution

Predicted band size: 43 kDa **Observed band size:** 53 kDa

Exposure time: 10 seconds

Blocking/Dilution buffer: 5% NFDM/TBST.



Western blot - Anti-p53 (phospho S37) antibody [EPR17353] (ab182164)

All lanes : Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) at 1/5000 dilution

Lane 1 : A431 whole cell lysate (Human epidermoid carcinoma)Lane 2 : A431 whole cell lysate treated with Lambda Phosphatase

Lysates/proteins at 10 µg per lane.


Secondary

All lanes : Goat Anti-Rabbit IgG H&L (HRP) (<u>ab97051</u>) at 1/50000 dilution

Predicted band size: 43 kDa Observed band size: 53 kDa

Exposure time: 3 minutes


Blocking/Dilution buffer: 5% NFDM/TBST.



Dot blot analysis of p53 (phospho S37) peptide (Lane 1), and non-phospho peptide (Lane 2), labeled using ab182164 at 1/1000 dilution, followed by Goat Anti-Rabbit lgG, (H+L), Peroxidase conjugated secondary antibody (ab97051) at 1/1000 dilution.

Blocking/Dilution buffer: 5% NFDM/TBST.

Exposure time: 30 seconds.



Western blot - Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) **All lanes**: Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) at 1/5000 dilution

Lane 1: HEK-293 whole cell lysate (Human epithelial cells from embryonic kidney)

Lane 2: HEK-293 whole cell lysate treated with Lambda Phosphatase

Lysates/proteins at 10 µg per lane.


Secondary

All lanes : Goat Anti-Rabbit IgG H&L (HRP) (<u>ab97051</u>) at 1/50000 dilution

Predicted band size: 43 kDa **Observed band size:** 53 kDa

Exposure time: 3 minutes

Blocking/Dilution buffer: 5% NFDM/TBST.



[EPR17353] (ab182164)

Anti-p53 (phospho S37) antibody [EPR17353] (ab182164) at 1/1000 dilution + Saos-2 whole cell lysate (Human osteosarcoma cell line) at 10 μ g

Secondary


Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/50000 dilution

Predicted band size: 43 kDa

Exposure time: 3 minutes

Blocking/Dilution buffer: 5% NFDM/TBST.

Saos-2 doesn't express p53.



Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery

- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit https://www.abcam.co.jp/abpromise or contact our technical team.

Terms and conditions

• Guarantee only valid for products bought direct from Abcam or one of our authorized distributors